Danaher’s Bioprocessing Outpaces Weak Life Sciences Outlook

Date of Call: Jan 28, 2026

Financials Results

• Revenue: $6.8B in Q4, up 2.5% core growth; $24.6B for FY 2025, up 2% core growth.
• EPS: $2.23 adjusted diluted net earnings per common share in Q4, up 4% YOY; $7.80 for FY 2025, up 4.5% YOY.
• Gross Margin: 58.2% adjusted gross profit margin in Q4, down 130 basis points YOY.
• Operating Margin: 28.3% adjusted operating profit margin in Q4, down 130 basis points YOY.

Guidance:

• Core revenue growth for full year 2026 anticipated in the 3%-6% range.
• Adjusted diluted EPS guidance for full year 2026 in the range of $8.35-$8.50.
• Q1 2026 core revenue expected up low single digits.
• Q1 2026 adjusted operating profit margin expected approximately 28.5%.
• Bioprocessing: high single-digit core revenue growth expected for full year 2026, with consumables leading and equipment expected to be approximately flat.
• Life sciences: core revenue expected to increase 0.5% for full year 2026, with modest end market improvement but growth below historical levels.
• Diagnostics: core revenue expected to increase low single digits for full year 2026, with mid-single-digit growth outside of China and respiratory revenue expected to be approximately $1.8B for full year 2026.

Business Commentary:

Bioprocessing Strength and Growth Outlook:

• Danaher's bioprocessing segment increased 6% in core revenue for Q4, with high single-digit growth in consumables and mid-single-digit growth in equipment.
• The growth is supported by robust demand for commercialized therapies, particularly monoclonal antibodies, and an improving capital spending environment.

Diagnostics Segment and Respiratory Revenue:

• The diagnostics segment reported a 2% core revenue increase in Q4, with mid-single-digit growth globally, notably in immunoassay.
• Respiratory revenue exceeded expectations at $500 million due to customer purchases anticipating an active respiratory season.

Life Sciences and Market Recovery:

• Danaher's life sciences segment saw a 0.5% increase in core revenue, reflecting a modest recovery in pharma and stable biotech demand.
• The recovery is linked to improved pharma investment following the resolution of Most Favored Nation deals and increased confidence in the market.

Cost Management and Margin Improvement:

• The company reported a 28.2% adjusted operating profit margin for the full year 2025, with a 145% free cash flow to net income conversion ratio.
• This improvement was driven by disciplined execution of cost savings initiatives, offsetting tariff-related cost pressures.

Guidance for 2026 and Core Revenue Growth:

• Danaher anticipates 3%-6% core revenue growth for 2026, with an adjusted diluted EPS guidance range of $8.35-$8.50.
• The outlook is based on gradual end market improvements, strong positioning in biologics, and the ongoing recovery in diagnostics.

Sentiment Analysis:

Overall Tone: Positive

• Management described 'better-than-expected performance across the portfolio' and a 'strong finish to the year'. They noted 'continued strength in our bioprocessing business, along with improving momentum in diagnostics and life sciences' and that 'the combination of our differentiated portfolio... positions Danaher for long-term value creation'. They also expressed being 'encouraged by the momentum building across our portfolio and expect growth to accelerate as end markets continue to improve'.

Q&A:

• Question from Michael Ryskin (Bank of America): How much conservatism is embedded in the 3%-6% core revenue guide, and where are potential upside levers?
  Response: The guide is based on continued recovery in end markets; upside could come from improved life science end markets and better-than-high-single-digit bioprocessing growth.

• Question from Michael Ryskin (Bank of America): What were bioprocessing order book and book-to-bill ratios in Q4, and how do they support the 2026 outlook?
  Response: The order book fully supports high single-digit 2026 growth; book-to-build for consumables is around 1, and equipment orders increased sequentially for three consecutive quarters.

• Question from Tycho Peterson (Jefferies): What drove SCIEX's strength, and where are end markets turning?
  Response: SCIEX's mid-single-digit growth was driven by innovation (ZenoTOF 8600), continued improvement in the pharma end market, and robust clinical/applied markets, while academic/government remained muted.

• Question from Tycho Peterson (Jefferies): How should we think about full year margin progression and incrementals?
  Response: Earnings will follow the trajectory of core growth, with second half benefiting more from 2025 cost actions, leading to a low single-digit growth build through the year.

• Question from Tycho Peterson (Jefferies): Any commentary on bioprocessing trends in China?
  Response: Bioprocessing in China is expected to grow in 2026, with underlying activity strengthening due to biotech market momentum from monetization opportunities.

• Question from Scott Davis (Melius Research): What was the post-restructuring impact beyond margin?
  Response: Traditional Danaher Business System productivity improvements included consolidating rooftops, driving process efficiency, and reducing associates, resulting in significant, sustainable cost savings.

• Question from Scott Davis (Melius Research): Are you seeing a big pickup in orders in January due to flu season?
  Response: ILI was high in late Q4, but testing remains robust; Q1 respiratory revenue is expected to be around $500 million.

• Question from Doug Schenkel (Wolfe Research): Why wasn't equipment growth guided higher given strength in Q4 and favorable comps?
  Response: Equipment growth in Q4 is encouraging but just one quarter; due to the unpredictable environment, guidance starts with equipment flat for 2026.

• Question from Doug Schenkel (Wolfe Research): What is the M&A environment and your readiness to be more aggressive?
  Response: M&A environment is more constructive with moderated valuations and interest rates; balance sheet is primed, and discipline on end markets and financial models remains.

• Question from Jack Meehan (Nephron Research): What are the thoughts on Q4 as a jumping-off point for 2026 in life sciences, considering potential push-outs?
  Response: End markets are expected to continue gradual improvement through 2026, with pharma showing growth for three consecutive quarters and academic/government still muted.

• Question from Jack Meehan (Nephron Research): Can you break down the margin puts and takes for 2026?
  Response: The EPS guide assumes low-end core growth, ~35-40% fall-through, a $0.30 benefit from 2025 cost actions, and FX/netting to zero.

• Question from Patrick Donnelly (Citi): What drove the Q4 life sciences improvement, and what is needed for 2026 growth?
  Response: Q4 outperformance led by SCIEX and Beckman Coulter Life Sciences, partly due to a budget flush in pharma; 2026 upside depends on academic/government stabilization and biotech funding environment improvement.

• Question from Patrick Donnelly (Citi): What is the path back to long-term revenue growth (LRP)?
  Response: Too early for specific 2027 comments, but long-term framework intact; as end markets recover (biologics, life science research, diagnostics), high single-digit growth will return over time.

• Question from Dan Leonard (UBS): How sensitive is the biotech segment to funding improvements?
  Response: Biotech represents about 10-15% of bioprocessing; improved orders have been seen but are early days, and most bioprocessing growth is driven by commercial volume.

• Question from Dan Leonard (UBS): How are reshoring conversations trending with customers?
  Response: Reshoring is advancing; equipment investment has been muted despite strong consumables demand, suggesting potential catch-up and a possible long-term investment cycle.

• Question from Dan Brennan (TD Cowen): Is bioprocessing growth slowing in 2026 given the guide?
  Response: No change to bioprocessing outlook; consumables expected high single-digit growth, equipment flat for the year, with discovery/medical offsetting in the segment.

• Question from Dan Brennan (TD Cowen): What are you seeing in pharma within life sciences, and can it recover in 2026?
  Response: Pharma has shown growth for three consecutive quarters, a recovery post-MFN deals; it is expected to continue improving, with clinical/applied markets stable.

Contradiction Point 1

2026 Life Sciences Revenue Growth Outlook

The expected trajectory for life sciences revenue growth appears inconsistent.

Okay, let's see. The user wants me to rewrite the earnings call question into a concise version. The original question is about the life sciences guide, asking if Q4 is a good starting point for 2026 or if there were push-outs from earlier in the year, and also about the underlying trends.First, I need to make sure I capture all the key elements. The main points are: life sciences guide, Q4 as a jumping-off point for 2026, possible push-outs from earlier in the year, and underlying trends. The user wants it concise, so I should combine the parts without losing meaning.The original question has two parts separated by "or" and then another part about trends. Maybe I can combine the first two into one question. "Is Q4 a good starting point for 2026, or were there push-outs from earlier in the year?" Then add the part about trends. So, "Are there underlying trends influencing this?" That seems to cover it.Check the constraints: output only the rewritten question, no explanations, end with a question mark. Make sure it's all in one sentence. Maybe combine them into a single question. Let me try: "Is Q4 a good jumping-off point for 2026 in the life sciences guide, or were there earlier push-outs? What are the underlying trends?" Wait, the user wants it as one question? Or two? The original has two separate questions. But the example might have combined them. Let me check the input again.The input has two parts: one about Q4 and push-outs, the second about trends. The user might want them as separate questions. But the output constraints say to end with a question mark. Maybe it's acceptable to have two questions. But the example in the input might have two. Let me see the original input: "Regarding the life sciences guide, is Q4 a good jumping-off point for 2026, or could there have been push-outs from earlier in the year? What are the underlying trends?" So two questions. The user wants the rewritten version to be concise. Maybe combine the first two parts into one question and keep the second as another. But the output must be only the rewritten question. Wait, the user says "output only the rewritten question" but the input has two questions. Do I need to combine them into one? Let me check the example given in the problem. The input is two questions, but the output example (if any) isn't provided. Hmm. The user's instruction says to rewrite the input into a concise question. So perhaps combine them into a single question that captures both aspects. Let me try: "Is Q4 a good jumping-off point for 2026 in the life sciences guide, or were there push-outs from earlier in the year, and what are the underlying trends?" That's one question with two parts. But the original had two separate questions. However, the user might prefer it concise, so combining makes sense. Let me check the wording. The original says "is Q4 a good jumping-off point... or could there have been push-outs..." So the first part is a yes/no or either/or question, and the second is about trends. Maybe rephrase to "Is Q4 a good starting point for 2026 in the life sciences guide, considering potential push-outs from earlier in the year, and what underlying trends are at play?" That's a bit long but concise. Alternatively, "Is Q4 a good jumping-off point for 2026 in the life sciences guide, or were there earlier push-outs, and what are the underlying trends?" That's shorter. Let me make sure it's all included. Yes, "life sciences guide", Q4 vs push-outs from earlier, and underlying trends. The user might prefer the shortest possible. Let me go with: "Is Q4 a good jumping-off point for 2026 in the life sciences guide, or were there earlier push-outs? What are the underlying trends?" But the user wants only one question. Wait, the input has two questions. The output can have two questions if needed. The constraints say "output only the rewritten question"—so maybe two questions are allowed as long as they are concise. Let me check the example again. The input has two questions separated by a question mark. The output example isn't given, but the user's instruction says "end with a question mark". So maybe the user expects one question. Hmm. Alternatively, maybe the user wants to combine both into one question. Let me try: "Is Q4 a good jumping-off point for 2026 in the life sciences guide, considering potential push-outs from earlier in the year, and what underlying trends are influencing this?" That's one question. It includes both the push-outs and the trends. That seems to cover both parts. Let me check if that's concise. Yes. So the - Jack Meehan (Nephron Research)

2025Q4: The outlook assumes **continued gradual improvement**... The **pharma end market** (3rd consecutive quarter of growth) is expected to keep improving... The **academic and government segment** may still be choppy but is expected to moderate over time. - [Rainer Blair](CEO)

For 2026, with Life Sciences growth projected at ~0%, what factors would drive positive growth, and is that scenario conservative? - Daniel Brennan (TD Cowen)

2025Q3: Life Sciences growth is assumed **flat for 2026**, similar to recent trends. - [Matt McGrew](CFO)

Contradiction Point 2

Bioprocessing Equipment Growth Outlook for 2026

Expectations for equipment growth shift from flat to potentially positive.

What are the bioprocessing order book and book-to-bill ratios for Q4 consumables and equipment, and how do they support the 2026 outlook? - Michael Ryskin (Bank of America)

2025Q4: The order book fully supports the **high single-digit 2026 growth outlook**... For **equipment**, orders increased sequentially for the third consecutive quarter, and revenue grew in Q4, indicating a positive trend. - [Rainer Blair](CEO)

What are the key factors impacting Q4 Biotech guidance, and what drives equipment recovery with the likelihood of a pickup next year? - Tycho Peterson (Jefferies)

2025Q3: Planning for 2026 assumes **equipment flat**. - [Rainer Blair](CEO) / [Matt McGrew](CFO)

Contradiction Point 3

Bioprocessing Equipment Outlook and Investment Timing

Contradiction on the expected recovery timeline for bioprocessing equipment spending.

Could you outline Q4 bioprocessing order book and book-to-bill ratios for consumables and equipment, and their impact on the 2026 outlook? - Michael Ryskin (Bank of America)

2025Q4: The order book fully supports the **high single-digit 2026 growth outlook**... For equipment, orders increased sequentially for the third consecutive quarter, and revenue grew in Q4, indicating a positive trend... - [Rainer Blair](CFO)

Considering trade uncertainty and a strong sales funnel, is bioprocessing equipment revenue expected to recover by 2025? - Rachel Marie Vatnsdal Olson (JPMorgan Chase)

2025Q2: Equipment is below historical trends... delays due to trade policy uncertainty. It takes years to build new pharma plants, so 2025 will be a down year for equipment. - [Rainer Blair](CFO)

Contradiction Point 4

Impact of Trade Policy on Customer Investment Timing

Contradiction on the specific impact of U.S.-China trade policy on customer capacity expansion plans.

Can you provide an update on customer conversations regarding reshoring over the past three months? - Dan Leonard (UBS)

2025Q4: Conversations indicate that equipment investment has been muted despite strong consumables demand... The reshoring trend is advancing... The combination of catch-up demand and reshoring could signal the early innings of a long-term investment cycle. - [Rainer Blair](CFO)

How are global trade tensions impacting operations geographically and across customer segments (pharma, industrial, applied markets)? Are orders being paused, canceled, or delayed, and do you anticipate improvement? - Michael Leonidovich Ryskin (Bank of America)

2025Q2: In pharma, capacity expansion plans are delayed as companies wait for clarity on tariffs; this is expected to clear in 6–12 months. - [Rainer Blair](CFO)

Contradiction Point 5

Bioprocessing Order Book Trends

The characterization of order book strength and its sustainability appears inconsistent.

What are the details on the bioprocessing Q4 order book and book-to-bill ratios for consumables and equipment, and how do they support the 2026 outlook? - Michael Ryskin (Bank of America)

2025Q4: The order book fully supports the **high single-digit 2026 growth outlook**. For consumables, a book-to-bill ratio of around 1 is optimal and was maintained. For equipment, orders increased sequentially for the third consecutive quarter, and revenue grew in Q4, indicating a positive trend, though it's too early to call a sustained trend given the previous period of muted investment. - [Rainer Blair](CEO)

What is driving the modestly raised full-year expectation in bioprocess—consumables or equipment—and what factors observed in the past three months have boosted confidence, along with any noted changes in customer order behavior recently? - Michael Ryskin (Bank of America)

2025Q1: Orders grew sequentially for the 7th consecutive quarter, with book-to-bill >1. Equipment orders and funnel trends are improving but not back to normal; no meaningful change in demand due to tariffs or reshoring efforts yet. - [Rainer Blair](CEO)